{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:22:25Z","timestamp":1790144545945,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"am","delay-in-days":437,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.lpm.2019.07.025","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T18:02:17Z","timestamp":1566496937000},"page":"859-870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Actualit\u00e9s dans les lymphomes \u00e0 petites cellules non folliculaires"],"prefix":"10.1016","volume":"48","author":[{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2019.07.025_bib0155","series-title":"INCa. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim. Synth\u00e8se","author":"Defossez","year":"2019"},{"issue":"Suppl 6","key":"10.1016\/j.lpm.2019.07.025_bib0160","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2019.07.025_bib0165","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.lpm.2019.07.025_bib0170","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.025_bib0175","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.lpm.2019.07.025_bib0180","first-page":"1134","article-title":"MALT lymphomas: pathogenesis can drive treatment","volume":"25","author":"Bertoni","year":"2011","journal-title":"Oncology (Williston Park)"},{"issue":"17","key":"10.1016\/j.lpm.2019.07.025_bib0185","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final Results of the IELSG-19\u00a0randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2019.07.025_bib0190","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2404782","article-title":"MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course","volume":"21","author":"Wohrer","year":"2007","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.lpm.2019.07.025_bib0195","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.lpm.2019.07.025_bib0200","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.lpm.2019.07.025_bib0205","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.lpm.2019.07.025_bib0210","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.lpm.2019.07.025_bib0215","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016\u00a0revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.lpm.2019.07.025_bib0220","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.lpm.2019.07.025_bib0225","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2017.1.371","article-title":"Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma","volume":"2017","author":"Thieblemont","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"48","key":"10.1016\/j.lpm.2019.07.025_bib0230","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","article-title":"Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the interlymph non-Hodgkin lymphoma subtypes project","volume":"2014","author":"Bracci","year":"2014","journal-title":"J Natl Cancer Inst Monographs"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.025_bib0235","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.lpm.2019.07.025_bib0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.07.025_bib0245","article-title":"Long-term follow-up analysis of 100\u00a0patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","author":"Lenglet","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.lpm.2019.07.025_bib0250","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.lpm.2019.07.025_bib0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67\u00a0as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J hematopathol"},{"issue":"Suppl 4","key":"10.1016\/j.lpm.2019.07.025_bib0260","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2019.07.025_bib0265","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European mantle cell lymphoma network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.lpm.2019.07.025_bib0270","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67\u00a0Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"C. J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2019.07.025_bib0275","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2019.07.025_bib0280","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.lpm.2019.07.025_bib0285","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2019.07.025_bib0290","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2\u00a0study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2019","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.lpm.2019.07.025_bib0295","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2019.07.025_bib0150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370\u00a0patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:05:22Z","timestamp":1760105122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219303379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0755498219303379"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.025","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s dans les lymphomes \u00e0 petites cellules non folliculaires","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}